AskAt received a Letters Patent dated January 4, 2024 for a use patent for its EP4 receptor antagonist in the treatment of NASH-associated liver cancer. The Notice was issued by the Office of the Controller General of Patents, Designs & Trade Marks (CGPDTM) in connection with Indian Patent Application No. 201827020731.0 (Filing Date: November 2, 2017). To date, in addition to India, the use patent has been granted in Canada, China, Europe, Hong Kong, Japan, Mexico, Russia, and the U.S.